Figure 4
From: Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway
Metformin improves olanzapine-induced hepatic/hepatocyte steatosis via downregulation of LXRα. LXRα mRNA levels in (A) mouse liver tissues, (B) HepG2 cells and AML12 cells. LXRα protein levels in (C) mouse liver tissues, HepG2 cells and AML12 cells. LXRα and PCSK9 mRNA and protein levels in HepG2 cells (D,F) and AML12 cells (E,F) treated with the LXRα plasmid. (G) ORO staining of HepG2 cells and AML12 cells treated with LXRα plasmid. PCSK9 (H) mRNA and (I) protein levels in HepG2 cells and AML12 cells treated with an LXRα antagonist. (J) ORO staining of HepG2 cells and AML12 cells treated with an LXRα antagonist. PCSK9 mRNA and protein levels in (K, M) HepG2 cells and AML12 cells (L, M) treated with metformin and LXRα plasmid. (N) ORO staining of HepG2 cells treated with olanzapine, metformin and LXRα plasmid. Ctrl, control; OLZ, olanzapine; MET, metformin. Data represent the mean ± SEM. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. control; *p < 0.05, **p < 0.01, ***p < 0.001 vs. olanzapine; &p < 0.05,&&p < 0.01, &&&p < 0.001 vs. olanzapine + metformin; one-way ANOVA plus Tukey’s post-hoc test.
